1. In Reply
- Author
-
Giovanni Brandi, Marzia Deserti, Francesco Vasuri, Andrea Farioli, Alessio Degiovanni, Andrea Palloni, Giorgio Frega, Maria A. Barbera, Stefania de Lorenzo, Ingrid Garajova, Mariacristina Di Marco, Antonio D. Pinna, Matteo Cescon, Alessandro Cucchetti, Giorgio Ercolani, Antonietta D’Errico-Grigioni, Maria A. Pantaleo, Guido Biasco, Simona Tavolari, Brandi, Giovanni, Deserti, Marzia, Vasuri, Francesco, Farioli, Andrea, Degiovanni, Alessio, Palloni, Andrea, Frega, Giorgio, Barbera, Maria A, de Lorenzo, Stefania, Garajova, Ingrid, Di Marco, Mariacristina, Pinna, Antonio D, Cescon, Matteo, Cucchetti, Alessandro, Ercolani, Giorgio, D'Errico-Grigioni, Antonietta, Pantaleo, Maria A, Biasco, Guido, and Tavolari, Simona
- Subjects
Cholangiocarcinoma ,Cancer Research ,Bile Ducts, Intrahepatic ,Treatment Outcome ,Bile Duct Neoplasms ,Oncology ,Chemotherapy, Adjuvant ,Humans ,h-ENT 1 ,Letters to the Editor ,Deoxycytidine ,Gemcitabine - Abstract
Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.
- Published
- 2016